Moses L, Katz N, Weizman A
Health Services, Division for Intellectual and Developmental Disabilities, Ministry of Social Affairs and Social Services, Jerusalem, Israel; Maccabi Health Services, South District, Israel.
Geha Mental Health Center, Petah Tikva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Eur Psychiatry. 2014 Sep;29(7):397-401. doi: 10.1016/j.eurpsy.2013.05.005. Epub 2013 Jul 9.
Low levels of blood cholesterol have been found in some children with autism spectrum disorders (ASD). Psychotropic medications, commonly used by people with ASD and people with intellectual disabilities (ID) are frequently associated with altered metabolic profiles.
We aimed to compare metabolic features of adults with ASD or ID with those of a community-based population.
Data on blood fasting glucose (FBG), lipid profile, liver enzyme profile, TSH, BMI, medications and diagnoses of 80 adults with ASD, 77 adults with ID and 828 control adults were drawn from medical charts/database. Candidates that used glucose or lipid lowering medications were not included.
Total-cholesterol levels of people with ASD and ID were significantly lower than those of the controls (168.3 ± 32.78, 168.2 ± 32.91, 185.4 ± 40.49 mg/dL, respectively, P<0.001) but after adjusting for gender, age and BMI and using Bonferroni correction, the significance was lost. Compared to controls, ASD and ID had significantly lower FBG (by -14.45 ± 1.81, -14.58 ± 1.54 mg/dl, respectively; P<0.001 for both) and liver enzymes, despite using psychotropic medications.
In contrast to other psychiatric patients receiving similar medications, people with ASD and ID have unaltered lipid profiles and lower glucose and liver enzyme levels compared to a community-based population.
在一些患有自闭症谱系障碍（ASD）的儿童中发现了低水平的血液胆固醇。ASD患者和智力残疾（ID）患者常用的精神药物常常与代谢特征改变有关。
我们旨在比较患有ASD或ID的成年人与社区人群的代谢特征。
从病历/数据库中提取了80名患有ASD的成年人、77名患有ID的成年人和828名对照成年人的空腹血糖（FBG）、血脂谱、肝酶谱、促甲状腺激素（TSH）、体重指数（BMI）、用药情况及诊断数据。使用降糖或降脂药物的受试者未被纳入。
患有ASD和ID的人的总胆固醇水平显著低于对照组（分别为168.3±32.78、168.2±32.91、185.4±40.49mg/dL，P<0.001），但在调整性别、年龄和BMI并使用Bonferroni校正后，这种显著性消失。与对照组相比，尽管使用了精神药物，但患有ASD和ID的人的FBG和肝酶水平显著更低（分别低-14.45±1.81、-14.58±1.54mg/dl；两者P均<0.001）。
与接受类似药物治疗的其他精神科患者相比，患有ASD和ID的人与社区人群相比，血脂谱未改变，血糖和肝酶水平更低。
